By contrast, expression of PI3KAP/XB130 has been reported in endocrine cancers such as thyroid cancer cells, and PI3KAP/XB130 knockdown inhibits cell proliferation, survival, migration, and invasion in these cell types (16, 23–25). Here, AFAP1L2 is linked to malignant endocrine neoplasm.